Podcasts about Case Western Reserve University

Inflation was over 4% last month, and President Trump says he loves it. What? Why'd he say that? Justin Buchler, Associate Professor of Political Science at Case Western Reserve University, joins us.

Send us Fan MailThe liver is the only organ in the body that can release stored glucose to prevent low blood sugar. So why has injected insulin never been able to reach it?In this clip from our episode “Finding a Solution for GLP-1 Side Effects”, host David E. Williams and Bob Geho, Founder and CEO of Diasome, break down the biological gap at the heart of diabetes treatment and how a father's decades of research into liver-targeted insulin delivery became the founding idea behind Diasome.

Can I restart my GLP-1? The answer is yes — but it requires a strategic plan.  In this episode I'm walking you through exactly what happens to your body when you restart a GLP-1, why the timing of your break matters more than you think, how to restart safely without landing yourself in misery, the biggest mistakes I see patients make, and how to get back on track without shame or guilt. Restarting doesn't have to mean starting completely over. But how you restart matters. Listen now!   Episode Highlights: Why restarting at your previous dose will make you seriously sick What happens to your hunger, cravings, and fullness signals when you restart How long you've been off determines your restart dose The critical question that changes everything: weeks vs. months off Why weight regain after stopping is biology, not failure 3 practical strategies to minimize side effects and rebuild tolerance How to stay mentally on track without shame or comparison   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Send us Fan MailEvery year, one in five adults with Type 1 diabetes experiences a dangerous drop in blood sugar that renders them unable to treat themselves. These severe hypoglycemic events are still happening, even though many patients now use continuous glucose monitors and automated insulin pumps.Why has this trade-off between long-term A1C control and dangerous sugar crashes persisted for over 30 years?Bob Geho, Founder and CEO of Diasome, joins host David E. Williams to unpack the results of the company's 200+ patient Phase 2B OPTI-2 trial of HDV™ insulin. The study was presented recently at the American Diabetes Association meeting in New Orleans.In the trial, five patients using standard insulin experienced severe hypoglycemic events. This compares with zero such events among patients receiving HDV™ insulin. Meanwhile, HDV™ insulin matched standard-of-care A1C control.Bob also shares how the HDV platform is being studied for its potential to reduce side effects in GLP-1 therapy and to address insulin resistance, considered the root cause of Type 2 Diabetes.

Dr. Lev Gonick is the Enterprise Chief Information Officer at Arizona State University, where he leads technology infrastructure, AI innovation, and smart city architecture for the nation's largest public university. An academic and technology pioneer for more than three decades, Lev has been a sitting CIO for 25 years, with prior leadership at Case Western Reserve University and co-founding regional digital equity initiatives like DigitalC. In this bonus episode of DGTL Voices, Lev tells Ed about growing up in an academic family, the pivotal 1993 university sabbatical that shifted his career into online learning, and why a university's success should be measured by who it includes rather than who it excludes. He also shares insight into ASU's radical new medical school program where every future doctor also graduates with an engineering degree to navigate the upcoming AI economy. Plus: the unique strategy he uses to stay ahead of tech trends by employing 350 student "coaches," why building true human relationships matters more than titles, and how getting lost in the kitchen as an amateur chef keeps him grounded. https://marxadvisory.com

By some counts as much as 96% of everything in the universe comes from dark matter and dark energy. And, up to now, both are completely invisible. Few in the field question this theory, but could there be alternatives? Dean chats with Professor Stacy McGaugh from the Department of Astronomy at Case Western Reserve University to learn more.

With the rise in use of artificial intelligence, the data center industry is booming across the country, and right here in Ohio. So many data center plans are underway in our state that Ohio has given up about $2 billion in tax breaks to these projects over the last two years alone. This is a far cry from the original estimate that the break would be closer to $266 million, leading Gov. Mike DeWine to put a pause on the incentive program just last week. Thursday on the "Sound of Ideas," we'll dive into how companies are rushing into Ohio to try to set up shop, while concerned citizens are pushing for moratoriums and even bans on these facilities. They share concerns legitimized by environmental and energy experts about the impact operating these facilities will be on our air and water quality and whether our existing power grid can handle what data centers require. There's also the concern of whether this industry which supports the advancement of AI will result in fewer jobs in the region. Meanwhile, places like New Albany, Ohio seem to have figured out how to coexist with this technology in a way that benefits the area. And Greater Cleveland Partnership has released a set of guidelines they believe communities should consider, while trying to determine whether any kind of data center is right for them before putting blanket bans in place. What is the right approach, to balance economic growth and protecting our planet? We'll try to answer that question with a panel of experts, concerned citizens and industry insiders. Guests: -Miranda Leppla, Director, Environmental Law Clinic, Case Western Reserve University School of Law -Jonathan Steirer, Interim Director, Great Lakes Energy Institute -Baiju Shah, President and CEO, Greater Cleveland Partnership -Michael Miller, Senior Director of Corporate Communications, Park Place Technologies -Will Hollingsworth, Concerned Citizen, Ravenna Resident

Attorney General Dave Yost reflects on 25 years in Ohio politics This is Ohio Attorney General Dave Yost's final week in office. He announced last month he is stepping down to take a job as the vice president of strategy for the Christian, conservative legal group, the Alliance Defending Freedom. Yost could not run for re-election to the attorney general office because of term limits. He planned to challenge for the Republican nomination for governor, but the Ohio GOP and President Donald Trump threw support to Vivek Ramaswamy early on in the process effectively ending Yost's primary chances. He leaves with six months left in his term. Gov. Mike DeWine tapped Ohio Department of Public Safety Director Andy Wilson to serve out the rest of Yost's term. Tuesday on the "Sound of Ideas," we'll hear from Ideastream's Statehouse News Bureau Chief Karen Kasler, who recently sat down with Yost for an exit interview for the "State of Ohio" on WVIZ-PBS. Yost reflected on his quarter-century in Ohio politics, why he decided it was time to leave for the private sector and why this opportunity was the right one for him. Guests:- Dave Yost, Attorney General, State of Ohio- Karen Kasler, Bureau Chief, Ideastream Statehouse News Bureau New research predicts rising temperatures will increase heat-related heart disease Extreme heat can increase the risk of heart attacks, strokes and other serious cardiovascular events, particularly among older adults and people with existing heart conditions. As summer temperatures begin to climb across much of the country, researchers are taking a closer look at what that could mean for public health. A new study from Case Western Reserve University, University Hospitals and the Cleveland Veterans Affairs Medical Center projects that as climate change leads to more frequent extreme heat events, heat-related heart disease could increase by 200% nationwide over the next 25 years. To end the hour, we'll talk with two of the researchers behind the study about what they found, who could be most affected and what can be done to reduce the risks. Guests:- Gokul Parameswaran, Research Associate, Cardiovascular Research Institute, School of Medicine, Case Western Reserve University- Salil Deo, M.D., Associate Professor, Department of Surgery, School of Medicine, Case Western Reserve University

You stopped your GLP-1 and now you're wondering can I just restart where I left off? Why am I so hungry again? Why are the side effects back? Did the medication stop working? These are questions I hear all the time in my practice. And the answer is not as simple as picking back up where you stopped. In this episode I am walking you through exactly what happens biologically when you stop a GLP-1, why restarting feels different than when you first started, how to restart safely, the common mistakes I see patients make, and how to get back on track mentally without shame. A pause does not erase your progress. But how you restart matters more than you think. Listen now! Episode Highlights: Why stopping your medication is not failure and why your biology is not your weakness What actually happens to your hunger, cravings, and fullness signals when you go off GLP-1s Why restarting at your old dose can land you in the emergency room How long is too long to be off and what dose to restart at based on your break The 3 most common restart mistakes  Practical tips to minimize side effects and rebuild tolerance the right way How to stay mentally on track without shame or comparison to your first journey Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

The Lev Effect by Sheldon Greene https://www.amazon.com/Lev-Effect-Sheldon-Greene/dp/173518490X Sheldongreene.com “Dazzling” A Feel-good Read for Divisive Times A small town Jewish old-folks home is converted to a boarding school and the residents are recruited to mentor the young. The Russian school director, Lev Kyol, stirs up controversy when he celebrates Palestinian national aspirations and honors and feeds the homeless. A victim of persecution for his beliefs, Lev seeks to shatter conventions and dissolve stereotypes. Word of his controversial work goes viral and the media suggests that he is the Messiah. Lev’s enemies seek to deport him. His message unifies the community. The Lev Effect is light-hearted yet serious modern-day Passion. A sequel to the critically acclaimed Lost and Found, the novel is larded with warmth, humor, engaging characters, and is a celebration of goodness. About the author Sheldon Greene is a San Francisco lawyer with a background in public interest high impact litigation. He is also President and Director of Oak Creek Energy a wind energy development company. Education: Graduated Magna Cum Lauda, Phi Beta Kappa, Omicron Delta Kappa, Delta Sigma Rho, Order of the Coif, Case Western Reserve University, undergraduate and law, fifth in Grand National Debate Tournament, Law Review Editor, Winner Dunmore Moot Court Competition, Contracts Prize.

Katie Tolles is the Head Women's Coach for Case Western Reserve University's rowing team and the Director of Communications for the Cleveland Rowing Foundation's Board of Directors. Katie speaks to host Elizabeth Emery about the beauty of teamwork, being on the water, coaching high school and college athletes, travel, fear, and jumping right into things.  Katie's rowing career began as a freshman walk-on at Marietta College. She knew nothing about the sport when she started, but quickly rose through the team, becoming a leader early on in the Women's 1V8+ & 1V4+ for her four years of undergrad. Katie pursued elite rowing at Vesper Boat Club on Boathouse Row in Philadelphia in 2016. That summer she and her teammates went on to win Club Nationals and Canadian Henley. Katie served as a founding coach for Magnificat High School and designed the branding for the rowing programs at Magnificat High School, Cleveland Foundry Juniors and Case Western Reserve University. Today, Katie is a competitive athlete who sculls on the Cuyahoga River. She recently placing 5th at The Head of the Charles. Sign up for Hear Her Sports newsletter at https://bit.ly/HHSnewsletter
 Get involved and support the show directly at https://bit.ly/givetoHHSpodcast
 Find all episodes at http://www.hearhersports.com/
 Learn more about Katie Tolles at https://katietollesdesigns.com/ Find Case Western Rowing at https://casewesternrowing.weebly.com/ Follow Katie on Instagram at https://www.instagram.com/kttolles/ Follow Katie on LinkedIn at https://www.linkedin.com/in/katie-tolles-uxmc-355959b8/

Rising costs, student debt and shifting workforce needs are putting more pressure on liberal arts colleges to demonstrate their value. But some proponents say a liberal arts education is about more than just preparing for a first job. It's about building skills for the many careers and changes that come after it.MPR News guest host Annie Baxter talks with guests about the future of liberal arts and higher education at a recent event sponsored by the Citizens League and Macalester College.Guests:Suzanne M. Rivera is the president of Macalester College. She previously served in academic and leadership roles at Case Western Reserve University, UT Southwestern Medical Center and the University of California–Irvine.B Kyle is the president and CEO of the St. Paul Area Chamber.Wendy Robinson is the assistant commissioner for Programs, Policies, and Grants at the Minnesota Office of Higher Education.

In this episode of The Get Down: Beyond Bitcoin, host Cleve Mesidor sits down with two-term SEC Commissioner Hester M. Peirce—affectionately known as "Crypto Mom" and "Crypto's Architect"—for an engaging conversation.As Commissioner Peirce prepares to conclude her impactful tenure at the SEC later this year, she shares her unique origin story, vision for a digital asset regulatory framework, and insights regarding inter-agency harmonization between the SEC and CFTC.Commissioner Peirce is not just a champion of crypto, she also holds the industry accountable and advances sound guidance to build a stable industry. This captivating discussion covers a variety of timely topics, including tokenization opportunities for smaller players, as well as advice for the crypto industry about how best to continue to advance crypto rulemaking going forward.Interview with SEC Commissioner Hester M. PeirceCommissioner Peirce discusses her regulatory journey since 2018, impending departure from the Commission, and enduring optimism for the transformative nature of the technology.Crypto Origin Story: How early conversations with Jerry Brito sparked an interest in blockchain technology before joining the SEC during pivotal market shifts.Regulatory Harmonization: A deep dive into harmonization efforts with the CFTC, building on previous work with former Commissioner Brian Quintenz to develop a coordinated strategy.Advice to Industry: Why builders should focus on solving real-world consumer/investor problems and build commercially viable products.Life After SEC: Plans to transition into teaching, while cheering on sound regulation from the sidelines.Memorable Milestones: Reflections and why meeting conviction-driven builders during market lows remains her favorite part of the job.Next Gen Crypto: Reflecting on how Gen Z will integrate blockchain technology, and a call to use crypto as a tool for societal unity rather than divisiveness.About SEC Commissioner PeirceHester M. Peirce was appointed by President Donald J. Trump to the U.S. Securities and Exchange Commission and was sworn in on January 11, 2018.Commissioner Peirce leads the SEC Crypto Task Force, which seeks to provide clarity on the application of the federal securities laws to the crypto asset market and to recommend practical policy measures that aim to foster innovation and protect investors.Prior to joining the SEC, Commissioner Peirce conducted research on the regulation of financial markets at the Mercatus Center at George Mason University. She was a Senior Counsel on the U.S. Senate Committee on Banking, Housing, and Urban Affairs, where she advised Ranking Member Richard Shelby and other members of the Committee on securities issues. Commissioner Peirce served as counsel to SEC Commissioner Paul S. Atkins. She also worked as a Staff Attorney in the SEC's Division of Investment Management. Commissioner Peirce was an associate at Wilmer, Cutler & Pickering (now WilmerHale) and clerked for Judge Roger Andewelt on the Court of Federal Claims.Commissioner Peirce earned her bachelor's degree in Economics from Case Western Reserve University and her JD from Yale Law School.Links from the episodeCONNECT WITH COMMISSIONER HESTER PEIRCE:Website: www.sec.govCONNECT WITH BUTTERSCOTCH MEDIA:Website: butterscotch.mediaSubscribe to Chews Tipsheet: butterscotch.media/subscribeFollow us on X: @butterscotch360 CONNECT WITH BUTTERSCOTCH MEDIA:Website: butterscotch.mediaFinTech TV Network: https://fintech.tv/category/the-get-down-podcast-series/Subscribe to Chews Tipsheet: butterscotch.media/subscribeFollow us on X: @butterscotch360

A patient finally decides to prioritize their health. They wait weeks for an appointment. We talk, we plan, and they leave with hope. Then the pharmacy calls with a price tag over $1,000 a month and that hope disappears. If that's happened to you, I made this episode for you. Because what most patients don't know is that there are real, legitimate ways to make this work and I'm breaking all of them down today. An insurance denial is not a verdict on your health or your worth. It just means we need to get strategic. Listen now!   Episode Highlights: Why I never let my patients stop at the first insurance "no" The Zepbound Lilly Direct self-pay program and what it actually costs The Wegovy NovoCare self-pay option and its introductory pricing Oral GLP-1 medications — who they're right for and why they may surprise you Manufacturer coupons, GoodRx, and savings tools most patients walk past How to appeal a denial and exactly what documentation can move the needle Why thinking long-term changes everything about affordability   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

People keep asking the same question: what's actually the difference between all these weight loss medications?  Ozempic. Wegovy. Mounjaro. Zepbound. Foundayo. Wegovy pill. Some of these medications are injections, some are pills, some are FDA-approved for diabetes, others for weight loss, and some are actually the same medication with completely different brand names. So I'm breaking it all down for you today — in plain language — because the confusion alone is keeping people from getting the treatment they need. The real problem isn't just the brand names. It's that without knowing exactly how these medications differ, patients end up on the wrong one, pay out of pocket unnecessarily, or give up when insurance denies them. You deserve better than that. Once you understand what each one actually does, the whole picture becomes much clearer. Listen now!   Episode Highlights: Why Ozempic and Wegovy are the same medication and why the difference still matters How tirzepatide (Mounjaro/Zepbound) works on two hormone pathways and why it tends to produce greater weight loss The new oral options — Foundayo and Wegovy pill — and who they're actually right for Real average weight loss numbers from clinical trials, by medication How insurance covers (or denies) each one and what I tell my patients when it does Who may be a candidate for these medications   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Case Western Reserve University School of Law Professor Atiba Ellis discusses gerrymandering in the wake of the Supreme Court decision in Louisiana v. Callais. University of Pennsylvania Law School Professor Jill Fisch joins Legal Face Off to discuss the latest developments in the Sam Altman trial. Illinois State Senator Sue Rezin joins Rich and Tina to discuss […]

This episode with Daniel Radigan is one I have been looking forward to for a while. Danny is a 3L at Case Western Reserve University School of Law and a finalist for Rhetoric's Moot Court Madness competition. Danny takes us down his journey, from growing up in Cleveland to playing Division I soccer as a goalie at Duquesne University, to working for his distant cousin Scott Lynch at a small probate firm in Chardon, Ohio, that ultimately sold him on going to law school.What stands out about Danny is just how much he has taken advantage of his time in law school. He has stacked clerkships and externships at the Milton Kramer Law Clinic, the U.S. Attorney's Office, the U.S. District Court for the Northern District of Ohio, and a summer associate position at Porter Wright, all leading up to a summer at Baker Hostetler and a federal clerkship lined up after graduation with a Judge in Pittsburgh, who he actually took a pre-law class with as a junior in undergrad. A full-circle moment if there ever was one. Danny also gets into his love of moot court, his thoughts on AI in legal writing, and his honest take on using Cicero throughout the Moot Court Madness competition.This was a fantastic conversation with a guy who is clearly going to make a great attorney one day!Danny's LinkedIn: https://www.linkedin.com/in/daniel-radiganBe sure to check out the Official Sponsors for the Lawyers in the Making Podcast:Rhetoric - Empowers your teaching and training with AI that strengthens learning, protects integrity, and proves authentic understanding, for students and professionals alike, with CICERO. Find them here: userhetoric.comThe Law School Operating System™ Recorded Course - This course is for ambitious law students who want a proven, simple system to learn every topic in their classes to excel in class and on exams. Go to www.lisablasser.com, check out the student tab with course offerings, and use code LSOSNATE10 at checkout for 10% off Lisa's recorded course!Start LSAT - Founded by former guest and 22-year-old superstar, Alden Spratt, Start LSAT was built upon breaking down barriers, allowing anyone access to high-quality LSAT Prep. For $110, you get the Start LSAT self-paced course, and using code LITM10, you get 10% off the self-paced course! Check out Alden and Start LSAT at startlsat.com and use codeLITM10 for 10% off the self-paced course!Lawyers in the Making Podcast is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Get full access to Lawyers in the Making Podcast at lawyersinthemaking.substack.com/subscribe

Stijn Schmitz welcomes Luke Gromen to the show. Luke Gromen is President and Founder of Forest For The Trees. Luke explores unprecedented global economic and geopolitical shifts, focusing on massive commodity supply disruptions and transforming monetary systems. He highlights several critical trends: the largest commodity supply flow disruption in history, unprecedented levels of globalization, sovereign debt, and market valuations. He argues that current global tensions, particularly around the Strait of Hormuz, could trigger significant economic challenges. The potential closure of strategic maritime routes could lead to dramatic supply chain breakdowns, potentially causing localized famines and massive economic disruptions. Gromen suggests that while the US dollar will remain widely used, it will no longer be the primary wealth storage mechanism. China is strategically positioning itself by establishing yuan-gold settlement systems and offshore clearing banks, effectively creating a multi-currency framework with gold as the pivotal settlement asset. Geographically, Gromen sees varied outcomes for different regions. He believes the United States has geographical advantages but warns against urban living during this transition. Europe appears most vulnerable, while Asian countries like China, Japan, and South Korea are potentially well-positioned to benefit from these shifts, particularly given their engineering capabilities and demographic dynamics. Regarding commodities, Gromen anticipates a generational trend favoring strategic metals like copper, silver, nickel, rare earths, and uranium. He predicts that future commodity trades will increasingly require value-for-value exchanges, moving away from paper-based transactions. The underlying theme is a fundamental restructuring of global economic systems, driven by supply chain fragilities, geopolitical tensions, and the need for more resilient, productivity-focused economic models. Gromen suggests this transition will likely involve significant inflation and economic recalibration, with gold playing a central role in the emerging monetary landscape. Timestamps: 00:00:00 – Introduction 00:00:44 – Unprecedented Energy Disruption 00:02:48 – Globalization and Debt Levels 00:05:00 – Equity Valuations Warning 00:07:20 – Market Pricing Liquidity 00:09:01 – Supply Chain Breakdowns 00:10:28 – Disruption Lag Effects 00:12:15 – Oil Policy Miscalculations 00:15:27 – Geopolitical Trade-offs 00:21:50 – Hubris vs Strategy 00:28:33 – China’s Strategic Benefits 00:33:56 – Monetary Order Shift 00:39:52 – Gold’s Reserve Role 00:45:06 – Future Debasement & Gold 00:49:46 – Regional Economic Outlooks 00:56:10 – Commodity Generational Trends 01:00:12 – New section Guest Links: X: https://x.com/lukegromen Website: https://fftt-llc.com/ Luke Gromen began his career in the mid-1990s in Research at Midwest Research before moving over to institutional equity sales and becoming a partner. While in sales, Luke was a founding editor of Midwest’s widely-read weekly summary (“Heard in the Midwest”) for the firm’s clients. He aggregated and combined proprietary research from Midwest with inputs from other sources. In 2006, Luke left FTN Midwest to become a founding partner of Cleveland Research Company. At CRC, Luke continued to work in sales and edit CRC’s flagship weekly research summary piece (“Straight from the Source”) for the firm’s customers. In 2014, Luke left Cleveland Research to found FFTT, LLC (“Forest for the Trees”), a macro/thematic research firm catering to institutions and individuals that aggregates a wide variety of macroeconomic, thematic, and sector trends in an unconventional manner to identify investable developing economic bottlenecks. Luke also provides strategic consulting services for corporate executives. He is a graduate of the University of Cincinnati and received his MBA from Case Western Reserve University and earned the CFA designation in 2003.

Medicare has spent years telling obesity patients: your medication isn't covered. Starting July 1, 2026, that may finally start to change. In this episode, I will break down the new Medicare GLP-1 Bridge Demonstration Program — what it is, who qualifies, and which medications may be covered. This is not just a policy update. For thousands of patients who have paid hundreds of dollars out of pocket or given up on treatment altogether, this pilot program represents a real opening. The biggest barrier to obesity treatment has never been willpower. It's been access.  This episode is your first look at what's coming and whether it applies to you. Episode Highlights: What the Medicare GLP-1 Bridge Program is  Which medications may be covered  The three eligibility groups by BMI and medical condition  Why this program matters beyond medication What the Treat and Reduce Obesity Act (TROA) is and why it still needs to pass Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

There are many treatment options for people with relapsing MS. Patients should be carefully monitored to assess treatment response, and a change in treatment approach should be considered if safety concerns emerge. In this episode, Teshamae Monteith, MD, FAAN, speaks with Ellen M. Mowry, MD, MCR, and Daniel Ontaneda, MD, PhD, coauthors of the article "Treatment of Multiple Sclerosis" in the Continuum® April 2026 Multiple Sclerosis and Related Disorders issue. Dr. Monteith is the associate editor of Continuum® Audio and an associate professor of clinical neurology at the University of Miami Miller School of Medicine in Miami, Florida. Dr. Mowry is the director of the Multiple Sclerosis Experimental Therapeutics Program and a professor of neurology at The Johns Hopkins University School of Medicine in Baltimore, Maryland. Dr. Ontaneda is the director of research at the Mellen Center for Multiple Sclerosis and a professor of neurology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio. Additional Resources Read the article: Treatment of Multiple Sclerosis Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @headacheMD Guest: @EllenMowryMD Full episode transcript available here Dr. Monteith: There are so many new treatment strategies for multiple sclerosis, which is a blessing, but it does come with the complexity of really just trying to nail down the approach. I just got finished talking to Drs Ellen Mowry and Daniel Ontaneda about their article on treatment of multiple sclerosis. We discussed relapses, weighing escalation versus early high-effective treatment and progressive disease. This is a must-listen-to podcast. I hope you enjoy it as much as I enjoyed talking to them.  Dr. Jones: This is Dr. Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr. Monteith: This is Dr. Teshamae Monteith. Today, I'm interviewing Ds Ellen Mowry and Daniel Ontaneda about their article on treatment of multiple sclerosis, which they wrote with Dr. Darin Okuda. This article appears in the April 2026 Continuum issue on multiple sclerosis. Welcome, both of you. How are you?  Dr. Mowry: Great. And thank you so much for having us.  Dr. Monteith: Absolutely. So, why don't you both introduce yourself?  Dr. Ontaneda: All right. My name is Daniel Ontaneda. I'm a neurologist at the Cleveland Clinic. I spend the majority of my time doing research, but I still dedicate about a day a week to seeing people with MS in clinic.  Dr. Mowry: I'm Ellen Mowry. I'm also a neurologist, but practice at the Johns Hopkins University. And similar to Dan, I mostly work on research, but also have an active clinical care component, taking care of people with MS.  Dr. Monteith: Well, thank both of you for writing this article and being on our podcast. I assume you guys have probably known each other for quite a while now.  Dr. Mowry: Yes. Dr. Ontaneda: Yes. Dr. Monteith: What inspired you to get into multiple sclerosis research and then clinical care?  Dr. Ontaneda: I always loved neurology, and I think a lot of us who go into neurology are attracted to the complexity of the human brain and how the nervous system works. But what really hit home to me was a family member of mine who had multiple sclerosis, and he was being treated in a time where we really didn't have super effective disease-modifying medications. And so, as I went through my medical career, I always kind of kept an eye on what was happening with multiple sclerosis, and I started my training at a time where it was really flourishing in terms of the medications available, so that's what inspired me to go into MS. It's a disease that we can definitely treat, and you can change outcomes for people. So, that was it.  Dr. Monteith: Yeah, that personal experience can be very impactful.  Dr. Mowry: My journey started, actually, because I was thinking about whether I wanted to be a physician at all, and I happened to land, just after high school, a position with a neurologist who happened to mostly focus on multiple sclerosis and taking care of folks with multiple sclerosis. And by the end of the summer, I knew I wanted to go to med school and I wanted to be a neurologist and I wanted to work with people with MS. I thought I would be a clinician exclusively, but I think as time went on and I started to hear the consistent questions that people I served were asking in the clinic and realizing that those questions could be turned into research projects that could address their concerns, I moved more and more towards research. Dr. Monteith: Great. There are a lot of really detailed information in the article, so I think that research mind is very useful, and I see that in the writing. Why don't we talk about the goal of the article? Dr. Ontaneda: So, I think the goal of the article was to set out kind of what the large view of what treatment for multiple sclerosis looks like. And, you know, many times we divide the treatment of multiple sclerosis into these large pillars, and I think that's what we did in the article. The first was, you know, what do you do with a person who has an MS attack or relapse? The second is, what medications do we use to treat the relapsing forms of multiple sclerosis where there is a lot of acute inflammation, focal inflammatory lesions that are occurring? And then the final one is, what do you do with individuals who have a more progressive form of the disease where they're accruing disability slowly and gradually? Dr. Monteith: And what were some of the main points? Dr. Mowry: Dr. Okuda provided a really nice section on the treatment of acute relapses in multiple sclerosis, and it's important to understand what we talk about when we are saying "relapse". For people with MS, many symptoms can fluctuate and occur and then get better over time, and sometimes people with MS use the same term of "relapse" to describe those symptom fluctuations. As neurologists, when we're thinking about relapse, we're really trying to think about symptoms that can be attributed to new focal inflammatory events somewhere in the central nervous system. Typically, these are accompanied---if you were to get an MRI at the same time---by a new lesion or MS spot, as I like to call them, on MRI scan. And so, it's important to distinguish when somebody is talking about symptoms, whether they are true new symptoms that could be mapped to a place in the central nervous system. Because alternatively, a lot of people who've had attacks or relapses in the past can have what we call pseudo-relapses, and these are essentially recrudescence of old symptoms, typically in a similar pattern as what had occurred in the past. And these can be brought out by things like fever or infection, sometimes stress. And pseudo-relapses are not thought to be due to new development of immune system-induced injury and therefore would be less likely to respond to treatment; and in fact, treatment may be contraindicated for those events. We also talked a little bit in that article about how relapses are treated, talking about the use of high-dose steroids for true new relapses, but also kind of cautioning that those are not necessarily free of concerns, especially if you have a pseudo-relapse or there could be an infection going on. And that ultimately, the decision as to whether to treat a relapse really is a shared decision-making because it's thought that although the steroids can speed up recovery from a relapse, they may not have a major impact on ultimate recovery. And so, a lot of the shared decision-making comes in here because for a mild relapse, you might choose to forego a course of high-dose steroids.  Dr. Monteith: Daniel, any other main points?  Dr. Ontaneda: Yeah. On the side of treating relapses, I think one of the other things that probably has changed a lot, at least during the course of my training, is that in the past, whenever we had identified a relapse, as Dr. Mowry has clearly defined, we would typically treat with intravenous high-dose corticosteroids, typically with methylprednisolone. And that was kind of our go-to. We would either do it in an infusion center or we would set it up with home care. And I think one of the things that our field learned over, I would say, the last five or ten years is there's an abundance of studies that show that you can give that same dose of methylprednisolone. Rather than giving it IV, you can give it orally. No pun intended, as I tell my patients, a lot of pills to swallow because we use fifty-milligram prednisone pills, and they have to take 1,250 a day. The pharmacy always pushes back on that many pills, but really the advantage of being able to take steroids orally that way for three to five days is really, I think, one, better for people with MS because they can do it in the comfort of their own home, and two, I think also when you look at the costs associated with that treatment, it is the most cost-effective option. Dr. Monteith: And what are some of the latest developments that you're really excited about that weren't in the article?  Dr. Mowry: A lot of the article focused on the approach to treatment of people with what we've traditionally called relapsing/remitting multiple sclerosis. So, this is the kind of MS that traditionally presents with a relapse or an attack initially, although some of that nomenclature is changing, actually. And the article focused a lot on the strategies surrounding treatment of somebody with newly diagnosed relapsing MS, and thinking about this vast number of disease-modifying therapies that are available to people with MS and their clinicians, and how to think about the strategy with respect to largely centered around the efficacy class of the medication, whether people should take an approach of using a higher-efficacy therapy---meaning a medicine that in clinical trials was more likely on average to suppress relapses as well as new lesions---or whether there's still a good argument for the case of using an escalation approach, using some of the more modest efficacy medications that also probably in general have lower risks, monitoring for response to treatment and changing if the medication isn't working. And so, there's still a lot of debate in the field, I would say, even though many people have moved towards a one-size-fits-all kind of approach. I think there's still a lot of debate in the field about the evidence underlying that. And, you know, full disclosure, Dr. Ontaneda and I are each running parallel and very complementary clinical trial programs to address this very question, the results of which should be available within the next year, year and a half.  Dr. Monteith: Well, we can't wait that long. Give me some clinical pearls to how we initiate these modifying therapies. Like, what are the pearls that we need to have in our mind?  Dr. Ontaneda: Yeah. I think when we think about starting the disease-modifying therapy in an individual who has an active form of multiple sclerosis, I think, you know, one of the cornerstones I would say of making that decision is shared decision-making. I think we tend to sit down with the patient and analyze the data that we have at hand, what we know about their multiple sclerosis, and we use several factors to inform how likely we think their disease is gonna be active or potentially might not respond to the initial treatment you give. And we look heavily at the MRI. The MRI is really a useful marker because it shows us, one, how many lesions a person might have---both, you know, where those lesions are and also kind of the amount of lesions. Lesions, certainly, that are in the spinal cord, a very large burden of diseases. A lot of active lesions, which we determine by the presence of contrast-enhancing lesions, really helps us inform on disease severity. I would say that was our number one tool that we use to decide and help us decide how we think that person's MS is gonna do over time. And then the second thing that we put into the equation also is, you know, how well do we think this person is going to tolerate our medications? All our disease-modifying medications act through suppression of the immune system, and we know that that carries some risks associated with it. Some of those risks are stuff like infections. Some of those can be simple infections that really don't have major consequences, but some of them can be quite serious, including the need for hospitalizations or prolonged antibiotic treatment courses. And so, we also look at what, you know, the underlying risk of a person has for infection. This kind of is determined by, one, A, how many infections they've had up to date, and also how much disability they had. I would say in our average patient who when we see them, they're probably typically pretty young, in their twenties, thirties, forties, they typically don't have a lot of infectious risks. And therefore, I think there's kind of a move to saying, "Well, actually their risk of infections is quite low." And we put that together with, you know, also what the preference of the patient might want. So, do they prefer to take a pill, for example? Do they prefer a medication where they receive that via infusion every six months and they don't really have to think about it? There are some people that don't like going into a hospital, and they might prefer an injection type of those medications. And so, after a complex discussion of all those factors, we take into consideration how much risk the patient wants to take as well, and we come up with a rational choice of a couple of medication options. So, I think it's challenging sometimes because we have over two dozen medications. There's the risk of you saying, "There are these twenty-four medications, you can pick one." And I think our job as neurologists is to kind of pare those down, talk about, in a person like yourself, these are the two or three medications that I would recommend using. Why don't you review them? And then we bring them back, and we kind of make a final decision with, one of the key factors that I think is important to remind people is that you're gonna start this medication, and we are gonna monitor to make sure it's working. We're gonna monitor to make sure you're tolerating it well. And although it's an important, the first decision you make, I think one key theme that we tell people is, we can revise our strategy whenever we like. We just have to think about it and do it in a way that we think is gonna make sure that their MS is under the best control. And then we think about the ultimate goal of treatment, which, in multiple sclerosis, is the absence of any attacks and also the absence of any new lesions on MRI. And that's where whether you are offering more of the high-effective medications or more moderate- or low-efficacy medications, that's where there's a little bit of controversy still in our field, and that's what our trials are trying to answer.  Dr. Monteith: Excellent. So now we've selected a particular option- and I love those points with shared decision-making, using the MRI to guide and then kind of risk tolerance related to infection. But now a patient's still having relapses, and I know the goal is zero, but, you know, there's some margin. What are the pearls to advance to more high-efficacy therapies?  Dr. Mowry: Yeah, that's a great question. Dr. Ontaneda in the article actually talked about the literature surrounding monitoring for breakthrough disease and when to say this much is too much, and there's actually not a definite right answer. It's clear that more active disease early in the course is probably more of concern than, say, developing, you know, a new spot in your fifties or something to that effect. So, different people have different thresholds. I know at our center, we tend to be pretty on top of making changes for breakthrough disease. So, what we typically do is reimage people about six months after they start a medication to establish a new baseline. And sometimes, because of delays in starting or because the medications take a while to kick in, there might be a new spot or two. So, if that's the case, I really only get concerned if the spots are also taking up the dye or enhancing to indicate they're really quite recent, and I think, "Ugh, that's not something I'd like to see six months after starting a medication." And so that otherwise is sort of the reference scan, moving forward, to evaluate the medication, and I have a very low threshold for changing, particularly if somebody is on a moderate-efficacy therapy. To me, I think, well, our goal of trying the moderate efficacy therapy is essentially to see if we could get away with a medicine that is probably, on average, safer and that will still work for your MS. But if the answer is no, I personally don't like to stick around too much on them. One caveat I would say is that if somebody develops what appears to be a new lesion or spot on higher-efficacy therapy, before presuming that that new area of activity is a definite new MS event, I always like to rethink carefully, did I get the diagnosis correct? Or could this be an early infection such as, you know, progressive multifocal leukoencephalopathy in people on natalizumab in particular? Because I see breakthrough activity so rarely in people on higher-efficacy therapies that I just like to rethink my diagnosis and the differential prior to making switches to, typically, another higher-efficacy therapy in that case. But that, again, is a little bit of shared decision-making. It's sometimes contextual. If a person is using a self-administered medication and they have a little breakthrough, sometimes you can solicit some history, saying, "Oh, I actually kind of stopped taking it for a few weeks because something was going on, and I really want to retry." And that's very reasonable as well. Dan, do you have any other thoughts?  Dr. Ontaneda: No, I think I agree. That's really close to how I practice myself as well, and the majority of people at my center. I think that we are learning that when you start a treatment, many times---depending on how deeply you look---you can find evidence of ongoing disease, and that's something that we struggle with. It's almost like we have tools to treat inflammation in terms of new MS lesions and new relapses. And so, when those are present, it's pretty clear that you probably have to switch medication. I think a slightly trickier issue is when, for example, you have a person who might be stable. They don't have an attack. But you notice that they're worsening, and they tell you they're worsening. I think our ability and tools for that is a little bit harder, and we recognize that that can actually happen fairly early in the disease. And that's why we're trying to rethink this mantra that we've had for many years, where we kind of divide MS up into relapsing and progressive, and we see people develop progressive MS 10 to 15 years after they've had a relapsing form of the disease. So, I think that's just a reality of clinical practice. And we don't have as many tools to treat that gradual worsening, which is kind of what the rest of our article spent some time talking about. Dr. Monteith: You've also written about the clinical trial long-term extension studies. And what are the few points that you take away from the emergence of these types of publications over the past few years? Dr. Mowry: Yeah, well, long-term extension studies can be really helpful to understand whether the findings that are evidenced during the randomized portion of trials themselves continue into a longer term. And for people with MS, understanding these data can be really helpful because, particularly when we're looking for impact of a given treatment or a strategy on disability worsening, often it takes longer than the short-term portion of the trial to truly understand if the medication or strategy has an impact on insidious worsening that Dan is speaking about. Many trials have demonstrated a short-term benefit, but we think a lot of times that benefit is probably because of the reduction in relapses, which sometimes leave a permanent mark on neurologic function. But the extension studies are trying to understand a little bit more about whether the effect on disability worsening is sustained, and also to look a little bit more deeply at long-term safety, especially when it comes to medications that do increase the risk of infection. The caveats, though, in interpreting those types of studies are that people drop out, and so probably the people who drop out of those studies are really different. They may be either less disabled and they think, "Oh, you know, I'm done. I feel good." Or potentially more disabled and they think, "Ugh, I have more things to do I've got to take care of. What's going on?" And so that kind of dropout can produce some bias in interpreting the results. Dan, any other thoughts?  Dr. Ontaneda: No, I think that's spot on. I mean, I think that when we're trying to decide on what general philosophy to use, right? Like, you're seeing a patient for the first time. They've recently been diagnosed with MS, and you have... you know, I kind of bin them into three options. You can start a low-efficacy, a moderate, or a high-efficacy medication. And the first piece of information you could use is clinical trials, and Dr Mowry very clearly identified why some of that data might be a little bit biased and isn't, you know, completely applicable to the patient who's in front of you. The second thing that we might look at is observational data, and there's a wealth of observational data that shows that, in general, people on higher-efficacy medications tend to do better over time. But one of the challenges we have is that there's always biases related to those observational study designs. And so, I think you have to interpret them with a little bit of caution because there are reasons people start specific medications in people. And when you look at them in a purely observational study, even if you do some fancy way of addressing those biases, such as propensity, there always is the possibility of some residual bias. You know, that's part of the reason why we're doing the trials that Dr Mowry described, because we really need kind of long-term evidence to show that these medications actually can affect disability ten, twelve years after started. And I think pragmatic clinical trials, like the ones we're running, are really gonna be the key to answer those questions. We all have our favorite approaches right now, but I think that the data to actually demonstrate what's best for people with MS is really needed.  Dr. Monteith: Great, and there's so much in this article. I mean, we didn't even touch on radiological isolated syndrome, monitoring MS therapeutically, and treatment of progressive MS. Any final take-home points?  Dr. Ontaneda: Yeah. Maybe I will touch a little bit on the side of progressive MS, because it has been, you know, the MS that we historically have not been able to treat as much. So, we described there's over two dozen therapies approved for relapsing forms of MS. For purely progressive forms of MS that don't have any evidence of activity, we really only have one approved therapy, and it appears that that therapy actually does work through active inflammation anyway. And in the article, we highlighted examples of studies that have been negative, but also some recent examples of studies that have been positive, specifically with a new class of medication called BTKI, or Bruton tyrosine kinase inhibitors. We just recently heard of a second molecule that also had positive results in this realm. So, we're excited that, you know, in the next four to five years-  Dr. Monteith: I'm sorry. Can you just go ahead and say what that molecule...You're leaving people hanging.  Dr. Ontaneda: One molecule is tolebrutinib, which already has a positive study in secondary progressive MS in individuals without activity. And then the second compound that has been studied with positive trial results, we only have summary results from that, is a medication called fenobrutinib. And we think these two compounds that are part of a single class, the hope is that maybe they can address some of that gradual worsening that occurs in MS. And then the question comes whether we should use those from the get-go or if we should just use them later. So, a whole sort of variety of different questions. But I think important to call out for clinicians that this area where we had no available treatments for so many years might be changing.  Dr. Monteith: Well, thank you both. I really loved this conversation. I learned a lot listening to both of you, and I look forward to your clinical trial results.  Dr. Mowry: Thank you so much for having us. Dr. Ontaneda: Thanks so much. It was our pleasure. Dr. Monteith: Again, today I've been interviewing Doctors Ellen Mowry and Daniel Ontaneda about their article on treatment of multiple sclerosis, which they wrote with Dr. Darin Okuda. This article appears in the April 2026 Continuum issue on multiple sclerosis. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr. Monteith: This is Dr. Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Andrew Medvedev became dean of the Weatherhead School of Management on July 1, 2024. His focus is on cultivating a culture of trust and belonging in the school, enhancing interdisciplinary collaboration and research, implementing impactful experiential learning, and creating a workplace in which innovation thrives. He envisions Weatherhead as the intellectual entrepreneur's home of choice.“I believe Weatherhead can be an audacious school solving the most urgent challenges  in management,” Medvedev said. “I believe we get there by fostering a culture of excellence and innovation, attracting bold talent, making critical investments, and focusing on impacting how people think and act.”Before returning to his alma mater, Medvedev was a managing director and portfolio manager at Morgan Stanley Investment Management. In 2016 Medvedev partnered with trustee Joe Sabatini (MGT '82) to create the school's Wall Street Trek. This alumni-funded program readies undergraduates for financial careers and links them with opportunities in NYC's financial community. Since its inception, about half of the program's 200 alumni have gone on to work on Wall Street. In 2018 Medvedev joined Weatherhead's visiting committee.Medvedev and his family immigrated to Cleveland from Russia in 1992. His ties to CWRU run deep: His mother, Irene Medvedev, served the School of Medicine for 22 years as a senior technologist, and he obtained his undergraduate degree in economics from CWRU in 1997. He earned an MBA from Harvard Business School in 2004.Medvedev lives in Shaker Heights with his wife, Christine, and their three children.

Your weight loss medication was denied. That moment of hope is gone. But this is not a 'you' problem. It's a system problem. In this episode, I break down why insurance denials for weight loss medications happen so frequently, and more importantly, what you can actually do about it. From formulary exclusions to step therapy requirements to the documentation timing that can reset your entire approval clock the barriers are real, but they are navigable. A denial does not mean you failed. It means you hit a wall in a system built with gaps. Understanding how that system works is the first step to getting through it. Listen to this episode to stop feeling defeated and start building your case.   Episode Highlights: Why insurers deny weight loss medications even when you clearly qualify What "step therapy" is and why it forces patients to go backwards The documentation timing mistake that can reset your approval from scratch How to appeal a denial and why an appeal is advocating, not begging Self-pay options now available when insurance won't budge   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Laboratory medicine professionals deserve a seat at the decision-making table for patient care, but labs still seem to operate in the background. Laborastories host Dr. Paul J. Jannetto sits down with Dr. Christine Schmotzer, an associate professor in the department of pathology at Case Western Reserve University, to explore what keeps clinical labs stuck in the shadows, how they can step out of them, and how taking this step can improve patient outcomes. With special guest: Dr. Christine Schmotzer   Hosted by: Dr. Paul J. Jannetto

Weight loss plateaus on GLP-1 therapies such as Wegovy and Zepbound are increasingly understood as a function of biological adaptation rather than patient noncompliance. In this episode I will be discussing CagriSema, an investigational combination therapy expected to launch between late 2026 and early 2027. The treatment combines semaglutide and cagrilintide, targeting complementary mechanisms that regulate appetite and satiety. Clinical trial data indicate weight reduction of up to 22.7%, suggesting improved efficacy relative to existing monotherapies. The development reflects a broader shift toward combination-based treatment models, consistent with approaches used in managing chronic conditions such as diabetes and hypertension.  Listen to the episode for a closer look at what this could mean for treatment pathways and patient outcomes. Episode Highlights: Why plateaus happen and what your body is actually doing What CagriSema is and how its two-ingredient formula works What the REDEFINE trials show including how it stacks up against Tirzepatide Who this medication is most likely to help Why the best plan is still the one that's working for you right now Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Send us Fan MailA metabolic view of Alzheimer's disease & the recent discovery of compounds that reverse advanced disease symptoms in mouse models by restoring mitochondrial health.TOPICS DISCUSSED:Classic Alzheimer's pathology: amyloid plaques and tau tangles identified over 120 years ago, long assumed to drive irreversible neuron loss.Limitations of amyloid focus: plaques appear in some cognitively normal brains; antibody therapies have shown limited clinical benefit.Metabolic perspective: brain energy failure as a tipping point where repair mechanisms are overwhelmed, linking genetics, injury, and aging.Neuroprotection via P7C3 compounds: discovered through hippocampal neurogenesis screen; preserves mitochondrial function and normalizes NAD/NADH ratio without elevating NAD excessively.Recovery in models: treatment after symptom onset reversed cognitive deficits, blood-brain barrier damage, oxidative stress, and axon issues in amyloid and tau mouse models, despite persistent plaques.Broader implications: energy restoration enables surviving neurons to function; similar protective effects seen in TBI and other organs under stress.ABOUT THE GUEST: Andrew Pieper, MD, PhD, is a board-certified psychiatrist and neuroscientist, professor at Case Western Reserve University, and director of the Brain Health Medicines Center at the Harrington Discovery Institute. He directs a research group focused on neuroprotection after brain injury and neurodegenerative disease.RELATED EPISODE:M&M 208: Glyphosate, Choline & Alzheimer's: Toxins & Nutrition to Prevent Neurodegeneration | Ramon VelazquezSupport the showHealth Products by M&M Partners:AquaTru: Water filtration devices that remove microplastics, metals, bacteria, and more from your drinking water. Through link, $100 off AquaTru Carafe, Classic & Under Sink Units; $300 off Freestanding models.OmegaQuant: At-home blood testing to see fatty acid profiles, including omega-3 fatty acids. Use link to see options and support M&M.SiPhox Health: Comprehensive, cost-effective bloodwork from the comfort of home. Use code TRIKOMES for 20% off.KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime)Seed Oil Scout: Find restaurants with seed oil-free options, scan food products to see what they're hiding, with this easy-to-use mobile app.SporesMD: Premium mushrooms products (gourmet mushrooms, nootropics, research). Use code 'nickjikomes' for 20% off.For all the ways you can support my efforts

In Episode 197, Dr. Melissa Pflugh Prescott shares her research as an assistant professor of nutrition at Case Western Reserve University (and formerly at the Universityof Illinois). Her research focuses on sustainable food systems and public health, and she is dedicated to reducing school food waste while simultaneously improving child nutrition.

In Episode 20 of the Finish Big Podcast, host Mark Dorman welcomes Laura Bonnet, Founding Director of the Center for Family Business at the Weatherhead School of Management at Case Western Reserve University. Established in 2023, the Center for Family Business was created to connect and equip multi-generational family enterprises to build stronger legacies. Laura brings a powerful blend of strategy, corporate leadership, and advisory experience to the role — having held executive positions at American Greetings and advisory roles at McKinsey & Company, as well as experience with General Motors and Disney. In this episode, Mark and Laura explore the unique dynamics of family enterprises, the challenges of multi-generational transition, governance, strategy, and the importance of intentional legacy building. This is a must-listen for family business owners navigating succession, leadership development, and long-term continuity. Mark and Laura Discuss: The Birth of the Center for Family Business – Why Case Western launched it in 2023. Family Business Complexity – Why governance and relationships matter as much as performance. Multi-Generational Transition – Preparing next-gen leaders early. Strategic Discipline – Lessons from McKinsey applied to family enterprises. Corporate vs Family Culture – Key differences in decision-making. Legacy Thinking – Moving from wealth creation to legacy stewardship. Emotional Capital – The unseen driver of family business success. Board Structures & Governance Models – Professionalising the family enterprise. Education & Community – The role of universities in supporting family firms. Balancing Growth & Harmony – Keeping business and family aligned. Connect with Mark Dorman: Succession Plus US LinkedIn: Mark Dorman LinkedIn: Succession Plus Facebook: Succession Plus (330)-416-9271 mdorman@succession.plus About the Guest: Laura Bonnet is the Founding Director of the Center for Family Business at the Weatherhead School of Management at Case Western Reserve University. Prior to launching the Center in 2023, she served in executive leadership roles at American Greetings and worked at McKinsey & Company advising clients across industries. Her career also includes experience with General Motors and the Walt Disney Company. Laura combines strategic expertise with a deep understanding of multi-generational enterprise to help family businesses build governance, leadership continuity, and sustainable legacies.

Halle Tecco is an investor, entrepreneur, and author of the new book Massively Better Healthcare. In this live conversation, she offers advice for aspiring health tech founders, reflects on why “hustle culture” needs to be kept in check, and makes the case that founders should become anthropologists of the problems they want to solve. Most importantly, she argues that today's founders need to be “bilingual” — fluent in both healthcare and technology.Halle and Claudia cover:The early days of Rock Health in a walkup office in SF's ChinatownHow she learned to be a founder without the grindWhy AI is growing faster in healthcare than in any other industryHalle says there is lots of opportunity to build businesses in the healthcare industry, but you need to pick something you are passionate about:“It is extremely hard to be a founder. It is 10 times harder to be a founder in healthcare… you're working on what I think are the most important problems that we will be able to solve, but it's also really challenging. [Make] sure you're picking a problem that you're genuinely very passionate about solving. That will help drive you and be your North Star when things get inevitably very, very hard. “Relevant LinksBuy Halle's book Massively Better HealthcareListen to Halle Tecco's Podcast “The Heart of Healthcare”Learn more about Rock HealthMenlo Ventures report on the state of AI in healthcareAbout Our GuestHalle Tecco is an entrepreneur, angel investor, and podcast host passionate about fixing our healthcare system. She is the founder of Natalist, which was acquired by Everly Health in October 2021. Previously, Halle founded and ran Rock Health, and was also an Adjunct Professor at Columbia Business School, teaching the first MBA-level course on digital health investing.A proud first-generation college graduate, Halle earned an M.P.H. from Johns Hopkins University, an M.B.A. from Harvard Business School, and a B.S. from Case Western Reserve University. She has served as a Board Member to the International African American Museum since 2018, and as an Advisor to the Harvard Medical School Department of Biomedical Informatics since 2014. Halle has appeared in The New York Times, The Wall Street Journal, and CNBC. She was named as one of Goldman Sach's Most Intriguing Entrepreneurs and listed on the Forbes 30 under 30. She has spoken at the Aspen Ideas Festival, CES, TechCrunch Disrupt, and was a SXSW Keynote speaker.SourceConnect With UsFor more information on The Other 80 please visit our website - www.theother80.com. To connect with our team, please email claudia@theother80.com and follow us on twitter @claudiawilliams and LinkedInSubscribe to The Other 80 on YouTube so you never miss our video extras or special video episodes!

If you're looking for weight loss options but don't want injections, things just changed in a big way. In this episode, I break down a new class of weight loss pills, including Foundayo (orforglipron), the newest GLP-1 option that was just approved. Unlike older treatments, this pill is designed to be simple. No fasting. No strict timing. You can take it with food or even coffee. We also look at how it compares to the oral Wegovy pill and what that means for people who want real results without shots. There are now two real pill options in the weight loss space, and choosing the right one is not about hype. It's about your lifestyle, your body, and what you can actually stick with long term.  We're entering a new era of weight loss treatment. And for the first time, you have choices that don't involve needles. Listen now to understand what's new and what actually matters before talking to your doctor.   Episode Highlights: How Foundayo works in the body How it compares to oral Wegovy What makes GLP-1 pills different from older weight loss meds Who these options may or may not be right for   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

In this episode of The Mentors Radio, Host Tom Loarie talks with Robert Spetzler, M.D., a world-renown neurosurgeon specializing in cerebrovascular disease and skull base tumors. He served as the J.N. Harber Chairman Emeritus of Neurological Surgery, and Director Emeritus, as well as President and CEO Emeritus, of the Barrow Neurological Institute in Phoenix, Arizona. Under Dr. Spetzler's leadership, the Institute grew from a regional center to a global destination for the treatment, education, and research of neurological conditions. He is also emeritus chair of neurosurgery at the Phoenix campus of the University of Arizona College of Medicine. Dr. Spetzler was involved in pioneering the technique of hypothermia and cardiac arrest (‘cardiac standstill’) for the treatment of difficult brain lesions, which, as he explains, “has allowed us to treat patients who otherwise had absolutely no other option.” He performed more than 6,000 aneurysm surgeries during his career, treating some of the most complex cases in the world. Just over 100 of those patients underwent cardiac standstill. Dr. Spetzler’s desire to pursue a medical career, and to treat all—especially patients—with dignity, took root when he was age 5, when he had contracted tetanus from a rusty nail. Tetanus at the time was usually fatal. In the middle of the night his parents rushed him to the hospital, doing what they could to make sure he stayed awake on the way (to avoid falling into a tetany attack). At the hospital, he became one of the first people to receive a new drug, penicillin, which saved his life. Later, during a medical teaching presentation of his case, with the young Spetzler included in the presentation, the doctor failed to treat his young patient with even the slightest degree of dignity. Dr. Spetzler never forgot what that felt like and treating others, especially his patients, with dignity remained first and foremost the rest of his life, including in his practice and in his leadership. Honored many times by professional societies, including the American College of Surgeons and the Congress of Neurological Surgeons, in 1994, Dr. Spetzler was chosen to be the Honored Guest of Congress of Neurological Surgeons. At age 49, he was the youngest recipient of this prestigious honor. Five years later, he received the Herbert Olivcrona Award (the “Nobel Prize of Neurosurgery”), among many other awards listed in his biography. Born in Stierhoefstetten, Germany, Dr. Spetzler moved with his family to the United States at the age of 11. He received his B.S. from Knox College in Galesburg, Illinois, and his doctorate of medicine from Northwestern Medical School in Chicago. His postgraduate training was completed at Wesley Memorial Hospital, Northwestern in Chicago. He completed a residency in neurosurgery at the University of California, San Francisco. He received board certification in September 1979 from the American Board of Neurological Surgery. In 1983 Dr. Spetzler left his position as associate professor of neurosurgery at Case Western Reserve University School of Medicine in Cleveland to assume a position as chair of the Department of Neurosurgery at Barrow Neurological Institute at Dignity Health St. Joseph's Hospital and Medical Center in Phoenix. He served as president and CEO of Barrow from 1986 to 2017. Also a prolific writer, Dr. Spetzler has published more than 300 articles and 180 book chapters and has co-edited multiple neurosurgical textbooks, including The Color Atlas of Microneurosurgery (2000).   LISTEN TO the radio broadcast live on iHeart Radio, or to “THE MENTORS RADIO” podcast any time, anywhere, on any podcast platform – subscribe here and don't miss an episode! SHOW NOTES: ROBERT F. SPETZLER, M.D. BIO: https://www.barrowneuro.org/person/robert-spetzler-md/ https://en.wikipedia.org/wiki/Robert_F._Spetzler https://alchetron.com/Robert-F-Spetzler NEWS / ARTICLES : Dr. Robert F. Spetzler Makes Neurosurgery History as Two-Time CNS Honored Guest — 2014 Top Doctor: Robert F. Spetzler, MD — Phoenix Magazine It’s Personal: Dr. Robert F. Spetzler

There's a new movie starring Zendaya and Robert Pattinson called 'The Drama' that is sparking a lot of discourse around spoilers, movie marketing, and what should be revealed in advance. This hour, we offer a few spoilers about the movie in order to talk about all of that. Plus, a look at plot twists. GUESTS: Olivia Montminy: A student at College of the Holy Cross Aisha Harris: Critic and host of Pop Culture Happy Hour at NPR. She is author of Wannabe: Reckonings with the Pop Culture that Shapes Me James Hanley: Co-founder of Cinestudio at Trinity College. Vera Tobin: Associate professor of Cognitive Science at Case Western Reserve University. She is author of Elements of Surprise: Our Mental Limits and the Satisfactions of Plot Music featured (in order): Don Giovanni, K. 527: Overture – W.A. Mozart as performed by Claudio Abbado and the Chamber Orchestra of Europe Unexpected – Jonah Platt Everybody Knows – Leonard Cohen Brilliant Disguise – Melissa Black Always the Last to Know – Del Amitri If I Knew Then – Johnny Mercer and the Pied Pipers Support the show: http://www.wnpr.org/donateSee omnystudio.com/listener for privacy information.

On this episode, Professor Hatsuo Ishida, PhD of Case Western Reserve University, joins the show to discuss the development of next-generation composite materials engineered for deep-space travel. He shares the origin of their work with ultra-high molecular weight polyethylene (UHMWPE) with hydrogen-rich polybenzoxazine resins, and how these materials have been engineered into composites that integrate […] The post ISS Tested Composites for Low Earth Orbit and Deep Space Travel first appeared on Composites Weekly. The post ISS Tested Composites for Low Earth Orbit and Deep Space Travel appeared first on Composites Weekly.

If Wegovy has helped you — but not enough — the answer may not be more willpower. It may be a higher dose. The FDA just approved a new 7.2mg version of Wegovy, and the clinical data is turning heads. In this episode, I break down everything you need to know about this new higher dose — what the research shows, who it's designed for, and what it actually means for your weight loss journey. Weight loss medicine just crossed a new threshold. This isn't just a bigger dose, it's a meaningful new option for people who need more help reaching goals that can transform their health. Listen now! Episode Highlights: Why 1 in 3 people on the standard Wegovy dose don't lose even 5% of their body weight and what the new dose does differently The Step Up Trial: what a 1,400-person, 72-week clinical study published in 2025 found about the 7.2mg dose How nearly half of participants lost 20% or more of their body weight numbers we typically only see with bariatric surgery The side effects you need to know about, including the new one that showed up in 23% of patients Who this higher dose is best suited for and who should wait How the dosing process works and what to do if side effects become uncomfortable Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Dr. Sheryl Kingsberg is the chief of the division of behavioral medicine at MacDonald Women's Hospital/University Hospitals Cleveland Medical Center and Professor in Reproductive Biology, Urology and Psychiatry at Case Western Reserve University. Her areas of clinical specialization include female sexual disorders, menopause, pregnancy and postpartum mood disorders, and psychological aspects of infertility. Dr. Kingsberg's primary research interests are in treatments for female sexual disorders, genitourinary syndrome of menopause (GSM) and reproductive mental health. She is an Associate Editor for Sexual Medicine Reviews and sits on the editorial boards of the journals Menopause and Climacteric.  She has over 100 peer-reviewed publications and numerous book chapters and has co-edited a multidisciplinary textbook on treating female sexual disorders. Dr. Kingsberg is a past president of The Menopause Society and The International Society for the Study of Women's Sexual Health. She currently serves as the Advocacy Committee Chair for The Menopause Society. And for full disclosure, Dr. Kingsberg was the principal investigator on the research for Milli, one of our sponsors.  If you want to catch up on other shows, just visit our website and please subscribe! We love our listeners and welcome your feedback, so if you love Our Better Half, please give us a 5-star rating and follow us on Facebook and Instagram. It really helps support our show! As always, thanks for listening!  

President Trump has been a powerful figure on the ballot…but how do Republicans perform when he isn't on the ballot? We'll break it down with Justin Buchler, Associate Professor of Political Science at Case Western Reserve University.

You're doing everything right — watching what you eat, trying to stay active — and still the weight won't budge. If you have PCOS, this isn't a willpower problem. It's biology. And once you understand the cycle driving it, you can finally start to break it. PCOS creates a vicious cycle between high androgens, insulin resistance, and weight gain and each one feeds into the others. Your body isn't working against you randomly. There are real mechanisms at play, and understanding them is the first step to taking back control. In this episode, I break down exactly what's happening inside your body with PCOS and what you can actually do about it. I'll walk you through the androgen-insulin connection, where and why your body stores fat differently, and what the latest international guidelines say about treatment including newer options like GLP-1 medications. If you've been frustrated, discouraged, or told it's just about eating less and moving more this episode will change how you see your body and your options. Listen now! Episode Highlights: Why high androgens and insulin resistance keep feeding each other and why that makes weight loss so much harder Where PCOS fat actually gets stored (and why it's more than a cosmetic issue) Why losing just 5–10% of your body weight can dramatically improve your symptoms What nutrition and exercise approaches the research actually supports for PCOS What GLP-1 medications like semaglutide are showing in women with PCOS and what you need to know before considering them Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

As digital change accelerates across healthcare, payors face an urgent need to modernize how they communicate, educate, and engage. The AI-Orchestrated Experiences portfolio from Adobe and IBM represents a new paradigm where data, design, and intelligence work seamlessly together to improve outcomes for every stakeholder. In this episode of the AI at Health series on The Beat Podcast, host Sandy Vance sits down with Melissa Geissler, Partner for Healthcare and Life Sciences Strategy and Transformation at IBM, and Ted Roman, Healthcare and Life Sciences Digital Strategy Principal at Adobe, to unpack one of the most exciting partnerships in healthcare AI right now. Together, IBM and Adobe are building AI-orchestrated experience solutions that help payers deliver personalized, seamless, and scalable member experiences without the white-glove price tag. From helping members find the right health plan to automating prior authorization and appointment booking, this episode is a must-listen for any payer, provider, or health tech leader who wants to understand where consumer experience in healthcare is headed next.  In this episode, they talk about: Healthcare is data-rich, but still behind every major retailer when it comes to personalized member experiences IBM and Adobe are combining platform capabilities, agentic AI, and change management into one integrated framework AI agents can now handle health plan selection, appointment booking, and benefits navigation for members Brokers serving small and mid-size employers are one of the most underserved audiences in healthcare technology The best AI strategy starts with defining the business problem first, then building the technology around it Social determinants of health data can now be integrated into personalized member recommendations Organizations that feel under-resourced are the ideal candidates for AI-orchestrated experiences The partnership is already live with clients and expanding into provider and life sciences use cases  A Little About Ted and Melissa: Ted Roman, PhD, brings over a decade of expertise in healthcare and life sciences research, management, technology, operations, and digital strategy to Adobe. He is a principal in the Digital Strategy Group, serving organizations globally pursuing more interconnected experiences. Prior to Adobe, Ted served the needs of Highmark Health and McKinsey & Company's clients. He holds a PhD in Computational Biology from the School of Computer Science at Carnegie Mellon University. He also earned bachelor's degrees in computer science and mathematics from Case Western Reserve University. Melissa Geissle is a Partner at IBM, leading Public Market activities, where she applies experience strategy and service design to solve complex innovation challenges and leads a diverse team of designers, researchers, analysts, and strategists to help organizations create meaningful stakeholder connections while improving market outcomes. Over two decades, she has partnered with healthcare, life sciences, government, and nonprofit organizations to define and execute digital health initiatives, applying data-driven insights and ecosystem platform capabilities to redefine strategic marketing, service, and digital engagement functions. Melissa holds a BA in Economics from Bates College and an MBA from Georgetown University's McDonough School of Business, and has participated in global corporate citizenship initiatives across the UK, South Africa, and Poland.

If you've been struggling to lose weight and your thyroid came back abnormal, it's natural to connect the dots. But here's what I need you to know, the thyroid is not the whole story. In this episode, I break down exactly what your thyroid does and doesn't do when it comes to your weight. Yes, hypothyroidism affects your weight. But research shows it typically causes only 5 to 10 pounds of gain — and most of that is water retention, not body fat. Treating it will help you feel better, but it won't magically melt the weight away. And please, do not ask your doctor for extra thyroid medication to speed up weight loss. It won't work — and it can seriously hurt you. If you've ever blamed your thyroid for your weight struggles, this episode will give you the honest, research-backed truth — and a clear path forward. Listen now! Episode Highlights: What hypothyroidism actually does to your metabolism and what it doesn't Why the weight you gain from an underactive thyroid is mostly water retention, not body fat What to realistically expect when you start thyroid medication Why taking extra thyroid hormone to lose weight can cause serious harm The four steps to take if you're concerned about your thyroid and your weight Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

The midterms are still months away, but how are things looking at the moment? Will the big issues right now be what decides the elections? We'll talk to Justin Buchler, Associate Professor of Political Science at Case Western Reserve University

Send us Fan MailCollege doesn't feel like a community by accident. It takes people behind the scenes who obsess over the details, fight for student leadership opportunities, and turn “a campus” into a place students actually belong.We sit down with Heather Willis, Assistant Director for Engagement at Case Western Reserve University, to talk about the real work of student affairs and student engagement. Heather walks us through how student organizations are supported, how big traditions like homecoming get built, and why school spirit is especially tricky at a high-achieving research university where students are laser-focused on academics. If you've ever wondered what student activities and leadership staff do all day, she makes it practical and human.We also go off-script in the best way: Cleveland life, Playhouse Square, trying “younger people” activities and feeling it the next day, plus hobbies that keep you sane like board games, fantasy reading, and learning pickleball. Heather shares what it was like working with Fiddy on the university spirit committee, what makes collaboration click with campus partners, and why throwback weekends can teach students the history of where they are.Before we wrap up, Heather plugs LEAP (Linking Employment Abilities and Potential), an organization supporting adults with disabilities across Cleveland through advocacy, independent living skills, and community activities. Listen, share it with someone who cares about higher education, student leadership, or campus culture, and if you enjoy the show, subscribe, leave a review, and send this to a friend.All music brought to you by former guest of the show SpeedoSubscribe for exclusive content: https://www.buzzsprout.com/1530455/support Buzzsprout - Let's get your podcast launched!Start for FREETactical BrotherhoodThe Tactical Brotherhood is a movement to support America.Dubby EnergyFROM GAMERS TO GYM JUNKIES TO ENTREPRENEURS, OUR PRODUCT IS FOR ANYONE WHO WANTS TO BE BETTER.ShankitgolfOur goal here at Shankitgolf is for everyone to have a great time on and off the golf courseSweet Hands SportsElevate your game with Sweet Hands Sports! Our sports gloves are designed for champions,Buddy's Beard CareBuddy's Beard Care provides premium men's grooming products at an affordable price.Deemed FitBe a part of our movement to instill confidence motivation and a willingness to keep pushing forwardWebb WesternWebb Western is for those who roll up their sleeves and do what it takes to get the job done. Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the showFollow us on all social mediaX: @mikebonocomedyInstagram: @mikebonocomedy@tiktok: @mikebono_comedianFacebook: @mikebonocomedy

On Jan. 22, the Trump Administration held a ceremony to launch the Board of Peace, a new international organization designed to implement peace in Gaza and other conflict areas.  Some have described the organization as President Donald Trump's alternative to the United Nations, which he has repeatedly criticized. So far, 24 countries have signed up, although none of the signatories are America's traditional allies. On Tuesday's "Sound of Ideas," we'll hear the latest installment of "Talking Foreign Policy," our quarterly series in collaboration with Case Western Reserve University, host Michael Scharf and a panel of experts discuss the implications of President Trump's Board of Peace. They'll also discuss how the current war with Iran impacts the mission of the Board of Peace. Does that conflict stand in contrast with President Trump's attempts at a global peace? Guests:- Michael Scharf, President, The American Branch of the International Law Association; Former Dean, Case Western Reserve University School of Law- Harold Hongju Koh, Professor & Former Dean of Yale School of Law; Former Assistant Secretary, The U.S. Department of State- Milena Sterio, Distinguished University Professor, Cleveland State University College of Law; Managing Director, The Public International Law & Policy Group- Leila Sadat, Professor, Washington University School of Law; Board Chair, The American Branch of the International Law Association- Jessica Peake, Director, The International and Comparative Law Program, UCLA School of Law

If you've been eating barely anything and the scale still won't move, the problem might not be that you're eating too much. It might be that you're not eating enough.  And there's science behind why. "Why am I not losing weight?" It's the most frustrating question in my clinic. And the answer often surprises people.  Today, I'm answering it publicly — with research, not guesswork. In this episode, I break down exactly what happens inside your body when you undereat, why cutting calories too aggressively can backfire, and the six practical steps to get your metabolism working for you, not against you. Listen now! Episode Highlights: Why eating too little triggers metabolic adaptation What the research says about how many fewer calories your body burns as a result of eating too little The three hormonal shifts that happen when you undereat  Why you lose muscle — not just fat — on a crash diet, and why that makes future weight loss harder Six actionable tips: the right calorie range, protein at every meal, strength training, diet breaks, and sleep Warning signs that you may already be undereating Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

“I have all these learned behaviors, and … was seeing them play out in my own family, with my own children, and thinking about the generational transference of hurt and wounds and wanting to do what I could to minimize that.” – Carrie Levine Certified nurse-midwife and functional medicine practitioner Carrie Levine has had a lifelong interest in deep exploration. She completed the Hoffman Process in 2024, having learned about patterns years earlier from reading Bob Hoffman’s book, No One Is to Blame. She truly understood Bob Hoffman’s realization that “No one is to blame.” Self-described as weird when young, Carrie explored a variety of unusual passions as a teen, including challenging activities in nature. In early adulthood, Carrie led women through outdoor experiential educational adventures, guiding them to become skilled and empowered in a variety of settings. Later, as she embarked on a new career in medicine, Carrie drew parallels between supporting women in nature and supporting them in the labor room. She found the skills and presence she’d gained earlier also empowered women during childbirth. Sharing her journey, Carrie highlights how she came to learn about herself. She is clear that she must be aligned with her Spiritual Self and reflects on how she doesn’t do well when she isn’t aligned. She now counsels her patients that optimal health can only come when we are aligned with our core self. Carrie refers many women to the Hoffman Process. She sees that women, especially parents, need to step away from their everyday lives to do deep healing work. Her experience now helps others realize the importance of aligning mind, body, and spirit for optimal wellness. Content Warning: This episode mentions the death of a child and suicide. Please use your discretion. If you or someone you know is suicidal, please call the National Suicide Prevention Lifeline at 800-273-TALK, or 800-273-8255. Or message the Crisis Text Line at 741 741. Listen on Apple Podcasts More about Carrie Levine: Carrie E. Levine, CNM, FMCP-M, is the founder of the Whole Woman Health Clinic and author of Whole Woman Health: A Guide to Creating Wellness for Any Age and Stage. A certified nurse midwife and Institute for Functional Medicine certified practitioner, she evaluates and treats most common women's health concerns by integrating gynecology and functional medicine. For more than two decades, Carrie has worked to help women find wholeness, connecting physical symptoms and test results with lifestyle choices and daily practices. Previously, Carrie practiced gynecology and functional medicine at the renowned Women to Women clinic in Maine (2006–2014), and earlier provided full-scope midwifery at Miles Memorial Hospital (now Maine Health Lincoln) in Damariscotta, Maine. She's known for deeply listening, “connecting the dots” among seemingly unrelated symptoms and emotions, and breaking personal health goals into attainable steps so clients can thrive emotionally, spiritually, and physically. Carrie earned a BS from Syracuse University, an RN and MSN from Case Western Reserve University, and a Nurse-Midwifery certificate from what is now the Frontier Nursing University.  She is a member of ACNM (national and Maine chapters), the Maine Nurse Practitioners Association, and the Institute for Functional Medicine. Learn more about Carrie and sign up for her free weekly newsletters featuring recipes, podcasts, articles, and more. Follow Carre on Instagram, Facebook, LinkedIn, and YouTube. As mentioned in this episode: The Medical Panel episode on The Hoffman Podcast: •   Healing, Hoffman, and Finding Safety Within The Relaxation Response by Herbert Benson •   Transcendental Meditation Biking in Nova Scotia – cycling tours Johari’s Window Macrobiotics Women to Women Healthcare Center Taos Pueblo, New Mexico Men Are from Mars, Women Are from Venus, by John Gray Ruth Lockhart, Founder of  Mabel Wadsworth Women’s Health Center, Bangor, Maine Health in Our Hands •   Christiane Northrup, ObGyn, Founder of Women to Women •   Deb Soule, Herbalist, Founder of Avena Botanical Doula Training The Community Nurse Midwifery Education Program, Frontier Nursing University, Kentucky Midwifery MaineHealth, Lincoln, Maine Sympathetic Nervous System Perfect Madness: Motherhood in the Age of Anxiety, by Judith Warner Marcelle Pick No One Is to Blame, by Bob Hoffman Hoffman Tools: Hand on Heart Recycling Patterns      

You've heard about the Wegovy shot. Now there's a pill — and the confusion is already spreading. Is it the same? Does it work as well? Can you take it with your other medications? In December, the FDA approved an oral form of semaglutide specifically for weight management and cardiovascular risk reduction. That's a game-changer — but only if you know how to use it correctly. Take it wrong and it won't work at all. In this episode, I will break down the five things you need to know about the new Wegovy pill. I will talk about the science behind SNAC technology, why this medication goes beyond weight loss, and what are the side effects to expect If you or someone you love is exploring weight loss medication options, this episode gives you the clarity to have a smarter conversation with your doctor. Listen now! Episode Highlights: Why the timing and conditions of how you take this pill are non-negotiable The science behind SNAC technology and why this pill can't just be swallowed with breakfast Why this medication goes beyond weight loss and also protects your heart What to do if you're already taking levothyroxine or other empty-stomach medications What side effects to expect,  and how much weight loss to realistically anticipate Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

In this episode of Talking Sleep, host Dr. Seema Khosla welcomes Dr. Reena Mehra, professor in the Division of Pulmonary, Critical Care and Sleep Medicine at the University of Washington in Seattle, and Dr. Dennis Aukley, professor in the Division of Pulmonary, Critical Care, and Sleep Medicine at MetroHealth Medical Center, Case Western Reserve University in Cleveland, to discuss the newly released AASM clinical practice guidelines for evaluating and managing obstructive sleep apnea in hospitalized adults. The guidelines address a significant gap in inpatient care: how to systematically screen for sleep apnea in hospitalized patients, prioritize high-risk groups, determine when and where to perform testing, and ensure appropriate outpatient follow-up. Dr. Mehra and Dr. Aukley explain the impetus behind developing these guidelines and the PICO question process used to examine existing evidence, acknowledging the challenges of working with limited data in this emerging field. The conversation systematically walks through the four key recommendations: in-hospital screening for OSA as part of an evaluation and management pathway, use of inpatient PAP treatment for newly diagnosed or untreated moderate-to-severe OSA, availability of sleep medicine consultation, and implementation of discharge management plans to ensure timely diagnosis and effective outpatient management. Practical implementation receives extensive attention. How should patients be screened—using STOP-Bang or facility-specific methods? Should screening be built into the EMR? Which patient populations and hospital units should be prioritized? Who performs the screening—sleep navigators, nursing staff, or hospitalists? Can sleep consultations be conducted via telemedicine at the bedside? The experts emphasize the critical need for a program champion and comprehensive education initiatives. Dr. Aukley shares invaluable lessons from his experience creating an inpatient sleep program, discussing what he wishes he'd known before starting and practical insights gained through implementation. A particularly frustrating issue receives attention: patients who bring their own PAP devices to the hospital but never have them set up or used during their stay. The guidelines address this common scenario and provide frameworks for ensuring treated patients continue therapy during hospitalization. Legal liability considerations are explored: What responsibilities exist for untreated patients diagnosed with OSA during hospitalization? What about high-risk patients who haven't been formally diagnosed? The experts discuss strategies for ensuring outpatient follow-up, recognizing that effective discharge planning is essential for translating inpatient identification into long-term management. Whether you're considering establishing an inpatient sleep program, frustrated by gaps in hospital-based sleep apnea care, or seeking evidence-based approaches to identifying and managing OSA in hospitalized patients, this episode provides essential guidance and practical implementation strategies. Join us for this important discussion about bringing systematic sleep apnea evaluation and management into the inpatient setting.

On the heels of an unprecedented military operation in Venezuela, the United States joined Israel in a direct attack on Iran, citing a variety of justifications for the attack, including a nuclear threat, a predicted strike, a desire for regime change, and decades of hostilities. More recently, widespread protests and a crackdown by the regime have dominated headlines. Congress has responded to this sudden escalation of the conflict with attempts to rein in the White House. Meanwhile, Iran and its proxies responded with multiple retaliatory attacks across the Middle East. Already, the conflict has disrupted air travel, fuel prices, the global stock market, and further rocked the instability of an already conflict weary Middle East. At the root of the issue are lingering questions regarding White House motives and exit strategies.rnrnrnAmbassador Gina Abercrombie-Winstanley is a 30-year diplomat with deep experience in the Middle East and serves on the board of the Middle East Policy Council. Avidan Y. Cover is a Professor of Law and Director of the Institute for Global Security Law & Policy at the Case Western Reserve University School of Law, where he writes and researches in areas of national security, human rights, civil rights, international law, and ethics. Manouchehr Salehi is a longtime member of the Cleveland Iranian community. Marti Flacks, CEO of the Cleveland Council on World Affairs will moderate.

If you're on Wegovy, Zepbound, Ozempic, or Mounjaro — and worried about what happens when you stop — this episode is for you. The fear of gaining it all back is real. But weight regain is not inevitable. It's manageable. And I'm going to show you how. "What happens when you stop your GLP-1?" This is one of the most common questions I get in my clinic every single week. It's time I answered it publicly — with science, not fear. In this episode, I break down exactly what happens in your body when you stop your GLP-1, why weight regain happens, and the five pillars you need to protect your results, whether you're stopping by choice or out of necessity. Listen now! Episode Highlights: The physiological reason hunger surges and metabolism slows when you stop GLP-1s  What the SURMOUNT-4 clinical trial tells us about weight regain after stopping Tirzepatide Who is at highest risk for regaining weight  The 5 pillars of weight maintenance: protein, resistance training, carb awareness, appetite retraining, and medication transition strategy Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''. Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Scot Lowry — Managing Partner and Co-Founder of PromiseONE CompaniesScot is the Managing Partner and Co-Founder of PromiseONE Companies, a Cleveland-based investment firm that helps purpose-driven entrepreneurs acquire and grow established businesses through Entrepreneurship Through Acquisition, or ETA. Prior to launching PromiseONE, Scot acquired and led Fathom, a digital marketing firm he grew more than 450% over a decade — an experience that became both the financial engine and talent incubator behind PromiseONE's long-term portfolio strategy. Today, Scot also serves as the Richard Osborne Professor of Entrepreneurship at Case Western Reserve University, where he teaches acquisition entrepreneurship and helps steward one of the nation's longest-standing ETA programs.In our conversation, Scot and I explore Cleveland's unique “right to win” in ETA and the decades-long lineage that traces back to his mentor, Richard Osborne. We talk about what it truly means to become a credible buyer, how to earn the trust of legacy sellers, and why understanding what matters most to them is the foundation of great dealmaking. We unpack the evolution of PromiseONE's patient capital model, the philosophy of “your dream is my dream,” and how Scot has helped multiple operators transition from employee to business owner. We also discuss negotiation, long-term ownership versus traditional private equity, mentorship, and a deeply personal crucible moment that reshaped Scot's leadership philosophy and sense of purpose.Scot is a thoughtful entrepreneur, investor, and teacher, and this was a really meaningful conversation — please enjoy.00:00 Introduction to Promise Partners and Scott Lowry03:08 Cleveland's Right to Win in Entrepreneurship05:51 The Role of Richard Osborne and Promise Partners08:57 Building Credibility as a Buyer12:07 The Evolution of Promise One Companies14:55 Understanding Legacy Sellers18:04 The Importance of Relationships in Deal Making20:55 Navigating the Acquisition Process23:48 Lessons from Fathom's Growth and Leadership27:06 The Philosophy Behind Promise One's Model37:56 Choosing the Path of Entrepreneurship40:06 Building a Community of Entrepreneurs43:13 Incubating New Business Ideas46:04 The Promise Partners Model48:46 Long-Term Vision and Patient Capital51:53 The Art of Deal Making56:03 Teaching and Mentoring Future Entrepreneurs01:00:13 Reflections on Personal Growth and Purpose-----LINKS:https://promiseone.com/about-us/https://case.edu/weatherhead/academics/entrepreneurship-through-acquisitionhttps://www.linkedin.com/in/scotlowry/-----SPONSOR:Roundstone Insurance — https://roundstoneinsurance.com/Roundstone Insurance is proud to sponsor Lay of The Land. Founder and CEO, Michael Schroeder, has committed full-year support for the podcast, recognizing its alignment with the company's passion for entrepreneurship, innovation, and community leadership.Headquartered in Rocky River, Ohio, Roundstone was founded in 2005 with a vision to deliver better healthcare outcomes at a more affordable cost. To bring that vision to life, the company pioneered the group medical captive model — a self-funded health insurance solution that provides small and mid-sized businesses with greater control and significant savings.Over the past two decades, Roundstone has grown rapidly, creating nearly 200 jobs in Northeast Ohio. The company works closely with employers and benefits advisors to navigate the complexities of commercial health insurance and build custom plans that prioritize employee well-being over shareholder returns. By focusing on aligned incentives and better health outcomes, Roundstone is helping businesses save thousands in Per Employee Per Year healthcare costs. Roundstone Insurance — Built for entrepreneurs. Backed by innovation. Committed to Cleveland.Cerity PartnersCerity Partners, a full-service investment and wealth management firm serving high-net-worth individuals, entrepreneurs, and business owners, is proud to sponsor Lay of The Land. The firm has local roots in Cleveland and across Ohio, and like this podcast, Cerity Partners advisors specialize in serving the interests of local entrepreneurs and business leaders. They understand how to manage the total picture of wealth, both personal and professional. Cerity Partners has a unified team of specialists who collaborate on almost every aspect of a client's financial life, including business ownership. The firm's national presence means it can offer the resources and specialized knowledge of the largest institutions with the independence and service of a neighbor. The Cerity Partners Cleveland team understands the complexity that comes with wealth, and they adhere to fiduciary standards. Discover the financial lay of your land.Learn more at ceritypartners.com/NPR or call 216-464-6266.-----Stay up to date by signing up for Lay of The Land's weekly newsletter — sign up here: https://layoftheland.ck.page/5f0c1e28faConnect with Jeffrey Stern on LinkedIn — https://www.linkedin.com/in/jeffreypstern/Follow Lay of The Land on X @podlayofthelandhttps://www.jeffreys.page/

On this episode of Food Allergy Talk, I welcome Dr. Zachary Rubin. Dr. Zachary Rubin is a double board-certified pediatrician and allergist/immunologist who practices at Oak Brook Allergists in the Chicago area. A nationally recognized medical educator and public health advocate, he shares evidence-based, accessible advice on allergies, asthma, and vaccines with over 4 million followers under the handle @rubin_allergy. Dr. Rubin earned his medical degree from Case Western Reserve University, completed his pediatrics residency at the University of Illinois College of Medicine in Chicago, and his allergy/immunology fellowship at Washington University in St. Louis. Outside of medicine, All About Allergies is his first book, offering a clear, compassionate guide to managing allergic diseases.Read My Articles on WebMD: https://blogs.webmd.com/food-allergies/lisa-horneThe Everything Nut Allergy Cookbook: https://www.simonandschuster.com/authors/Lisa-Horne/190009636The Food Allergy Talk Podcast: https://foodallergypi.com/the-food-allergy-talk-podcast/Food Allergy P.I. Blog: https://foodallergypi.comX: @foodallergypi & @fatalkpodcastInstagram: https://www.instagram.com/foodallergypi/ and https://www.instagram.com/foodallergytalk/ TikTok: https://www.tiktok.com/@foodallergypiEmail: foodallergypi@gmail.com

Today's guest on The Long View is Hilary Wiek. Hilary is a principal analyst at PitchBook, where she leads PitchBook's coverage of fund strategies and performance, publishing primary research on the alternative space. Hilary also leads PitchBook's coverage of the ESG and impact investing space. Hilary has over 20 years of experience in asset owner, manager, and advisory roles. Prior to joining PitchBook, she was the director of investments at the Saint Paul & Minnesota Foundations, where she handled portfolio management, impact and ESG investment, investment due diligence and monitoring, and investment operations. Before that, she worked in senior positions at Segal Rogerscasey, the South Carolina Retirement Systems Investment Commission, Buckingham Financial Group, Dayton Power & Light, and KeyCorp. Wiek received a master's degree in finance and economics from Case Western Reserve University and a bachelor's degree in business leadership and finance from the University of Puget Sound. She is based in PitchBook's Seattle office. PitchBook is a Morningstar company. Episode Highlights 00:00:00 Background in the Private Markets and Joining PitchBook 00:04:49 Drivers of Private Market Slowdown in 2026 and Pockets of Outperformance 00:14:15 Key Lessons for Investing in Private Market Funds 00:18:12 Private Market Fees, Hidden Volatility, and Valuations 00:20:38 Evergreen Investment Growth, Interval Funds, and Questions Investors Should Ask 00:32:26 Is It Worth It to Invest in Private Markets? 00:36:50 ESG, Impacting Investing, and Key Themes for 2026 00:41:05 Private Market Exposure in 401(k)s PitchBook Reports Discussed Benchmarking and Returns: Why Are There So Many Numbers? Evergreen Funds: We Have Questions The Evergreen Evolution The New Face of Private Markets in Your 401(k) US Evergreen Fund Landscape 2025 Impact Investing Update If you have a comment or a guest idea, please email us at TheLongView@Morningstar.com. Follow Christine Benz (@christine_benz) and Ben Johnson (@MstarBenJohnson) on X, and Christine Benz, Amy Arnott, and Ben Johnson on LinkedIn. Visit Morningstar.com for new research and insights from Christine, Ben, and Amy. Subscribe to Christine's weekly newsletter, Improving Your Finances. If you want more Morningstar podcasts, check out The Morning Filter and Investing Insights. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.